Clementia Pharmaceuticals Inc. (CMTA) Just Recorded A Sigfniciant Increase

March 14, 2018 - By Adrian Erickson

The stock of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) is a huge mover today! The stock increased 4.00% or $0.71 during the last trading session, reaching $18.46. About 105,987 shares traded or 32.29% up from the average. Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $585.51M company. It was reported on Mar, 14 by We have $19.01 PT which if reached, will make NASDAQ:CMTA worth $17.57 million more.

Analysts await Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) to report earnings on May, 23. After $-0.37 actual EPS reported by Clementia Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -10.81 % EPS growth.

More notable recent Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) news were published by: which released: “Clementia to Participate in Leerink Partners 7th Annual Global Healthcare …” on December 12, 2017, also with their article: “Clementia Announces Closing of Over-Allotment Option in its Initial Public …” published on August 21, 2017, published: “Bone disease biotech Clementia Pharmaceuticals sets terms for $100 million IPO” on July 21, 2017. More interesting news about Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) were released by: and their article: “Clementia Pharmaceuticals to Host Symposium at the 8th International …” published on June 05, 2017 as well as‘s news article titled: “Clementia Pharmaceuticals Readies $100 Million IPO” with publication date: July 31, 2017.

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company has market cap of $585.51 million. The Company’s lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. It currently has negative earnings. The firm is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.